Pro-Dex, Inc.
NASDAQ:PDEXMedical - Instruments & Supplies
+$3.54 today
- Market cap
- $204.61M
- Beta
- -0.00
- P/E (TTM)
- 17.1
- EPS (TTM)
- $3.75
Volume 0.04M
Average 0.04M
PDEX Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Pro-Dex, Inc.NASDAQ: PDEX
Financing Cash Flow · Q3 FY2026 · quarter ended Mar 2026
Financing cash flow turns negative
Q3 FY2026 financing cash flow was -$1.22M, compared with $1.93M a year earlier. Trailing-twelve-month financing cash flow was -$11.23M. Over 3 fiscal years it compounded at -28.2% a year.
Context
- Financing cash flow amounted to 0.4% of revenue in FY2025, down 7.5 pp from a year earlier.
- Financing cash flow grew in size in 2 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly financing cash flow holds near -$1.22M or moves back toward the trailing-twelve-month quarterly average of -$2.81M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (292K) USD
- Year-over-year change
- +93.2%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-06-30 | (292K) | +93.2% |
| FY2024 | 2024-06-30 | (4.27M) | -71.5% |
| FY2023 | 2023-06-30 | (2.49M) | -215.2% |
| FY2022 | 2022-06-30 | (790K) | +0.0% |
| FY2021 | 2021-06-30 | (790K) | — |
Financing Cash Flow vs competitors
How PDEX compares with its peers on the latest reported figures
- PDEX's LTM Mar 2026 financing cash flow of $11.23M is the 7th largest of the 9 companies compared; the peer median is $27.79M.
- Its year-over-year change of -1124.4% is the lowest of 9, against a peer median of +123.8%.
- Financing cash flow amounts to 15.0% of revenue for PDEX, versus a peer median of 920.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $196.88M | +891.4% | +160.2% | 49605.2% | |
| LTM Mar 2026 | $58.43M | +75.2% | +171.2% | 55651.4% | |
| LTM Mar 2026 | $49.08M | +8.7% | +182.8% | 955.9% | |
| LTM Mar 2026 | $35.04M | +172.3% | +87.5% | — | |
| LTM Mar 2026 | $20.54M | +350.1% | — | — | |
| LTM Mar 2026 | $18.76M | +4324.8% | +205.6% | 54.6% | |
| LTM Mar 2026 | $11.23M | -1124.4% | -28.2% | 15.0% | |
| LTM Mar 2026 | $9.64M | +42.3% | +253.4% | 17.2% | |
| LTM Mar 2026 | $504K | -99.1% | +2110.8% | 884.2% | |
| Peer median (excluding PDEX) | $27.79M | +123.8% | +182.8% | 920.1% | |
Competitors are the stored peer set for PDEX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Jun 2021 | FY2022 Jun 2022 | FY2023 Jun 2023 | FY2024 Jun 2024 | FY2025 Jun 2025 |
|---|---|---|---|---|---|
| Net Income | 4.57M | 4.57M | 7.07M | 2.13M | 8.98M |
| Depreciation & Amortization | 726K | 726K | 857K | 1.16M | 1.24M |
| Deferred Income Tax | (63K) | (63K) | 264K | (1.56M) | 140K |
| Stock-Based Compensation | 1.28M | 1.28M | 766K | 605K | 555K |
| Change in Working Capital | (6.54M) | (6.54M) | 396K | (225K) | (10.45M) |
| Accounts Receivables | (4.45M) | (4.45M) | 5.43M | (3.94M) | (2.55M) |
| Inventory | (4.24M) | (4.24M) | (3.49M) | 898K | (6.94M) |
| Accounts Payables | 1.99M | 1.99M | (1.15M) | 2.44M | 179K |
| Other Working Capital | 162K | 162K | (394K) | 376K | (1.14M) |
| Other Non-Cash Items | (820K) | (820K) | (3.9M) | 4.1M | (2.14M) |
| Operating Cash Flow | (847K) | (847K) | 5.46M | 6.2M | (1.68M) |
| Capital Expenditures | (1.67M) | (1.67M) | (974K) | (983K) | (1.25M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (334K) | (334K) | 0 | (1.25M) | 0 |
| Sales of Investments | 770K | 770K | 89K | 0 | 1.31M |
| Other Investing Activities | (33K) | (33K) | 0 | 0 | (304K) |
| Investing Cash Flow | (1.24M) | (1.24M) | (885K) | (2.23M) | (238K) |
| Debt Repayment | 8.79M | 756K | (809K) | (816K) | 3.48M |
| Common Stock Issued | 96K | 0 | 0 | 0 | 42K |
| Common Stock Repurchased | (5.54M) | (1.61M) | (1.55M) | (3.51M) | (3.5M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (4.14M) | 60K | (134K) | 50K | (305K) |
| Financing Cash Flow | (790K) | (790K) | (2.49M) | (4.27M) | (292K) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (2.87M) | (2.87M) | 2.09M | (305K) | (2.21M) |
| Free Cash Flow | (2.52M) | (2.52M) | 4.49M | 5.22M | (2.93M) |
Pro-Dex, Inc.
NASDAQ:PDEX
Intrinsic Alpha fair value
Locked
Current Price
$63.94
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.